Feb. 2 at 10:07 PM
$CALC Hopefully they had a plan before annoucing the cancellation. 14 ish mil in the bank as per last q3 filing. 9mil MC two other trial on the go. Burn rate is concerning at this point. 8 more days to non compliance. Eric W Roberts CHIEF BUSINESS OFFICER bought a bunch in nov 2025. They need a strong PR fast.
" We remain optimistic about Auxora's potential in acute inflammatory illnesses and look forward to finalizing the design of a pivotal trial in AP, pending FDA feedback, in the first half of 2026, while also advancing a second CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension."
